Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates (bardoxolone methyl and omaveloxolone) target the important transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.

 

 

Webcasts

03-01-2021

Reata Pharmaceuticals Fourth Quarter and Full Year 2020 Financial Results and Update on Development Programs

Webcast: click here

Press (03-01-2021): 
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results and Provides an Update on Clinical Development Programs

Press (03-01-2021): 
Reata Pharmaceuticals, Inc. Submits NDA for Company’s Lead Program: Bardoxolone in Alport Syndrome

Teleconference Information

Date: Monday, March 01, 2021
Time: 08:30 am ET
Audience Dial-in (toll-free): (866)270-1533
Audience Dial-in (international): (412)317-0797
Access Code: 10152707

Read more
 MP3
 PDF

11-09-2020

Reata Pharmaceuticals Third Quarter Financial Results and Update on Development Programs

Webcast: click here

Press (11-09-2020): 
Reata Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results and Provides an Update on Business Operations and Clinical Development Programs

Press (11-09-2020): 
Reata Announces Positive Results From Year 2 of the Pivotal Phase 3 CARDINAL Study of Bardoxolone Methyl in Patients with Alport Syndrome

Teleconference Information

Date: Monday, November 09, 2020
Time: 08:00 am ET
Audience Dial-in (toll-free): (844)348-3946
Audience Dial-in (international): (213)358-0892
Access Code: 2896858

Read more
 MP3
 PDF

08-10-2020

Reata Pharmaceuticals Second Quarter Financial Results and Update on Development Programs

Webcast: click here

Press (08-10-2020): 
Reata Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial Results and Provides an Update on Business Operations and Clinical Development Programs

Press (08-03-2020): 
Reata Pharmaceuticals, Inc. to Report Second Quarter 2020 Financial Results and to Provide an Update on Development Programs on August 10, 2020

Teleconference Information

Date: Monday, August 10, 2020
Time: 08:30 am ET
Audience Dial-in (toll-free): (800) 708-4539
Audience Dial-in (international): (847) 619-6396
Access Code: 49873533

Read more
 MP3
 PDF

Events and Presentations

04-15-2021

2021 WCN Poster

Poster: Roser Torra, MD, PhD, Universitat Autonoma de Barcelona, Barcelona, Spain, presented Interim Analysis of the EAGLE Trial: An Open-Label Study to Assess the Long-Term Safety and Tolerability of Bardoxolone Methyl in Patients with Alport Syndrome

 PDF

04-06-2021

2021 NKF Posters

Poster: Arlene Chapman, MD, University of Chicago, Chicago, Illinois, USA, presented Trial Design for Phase 3 FALCON: Evaluation of the Safety, Tolerability, and Efficacy of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease

Poster: Bradley A. Warady, MD, Children’s Mercy Kansas City, Kansas City, MO, USA, presented KIDNEYCODE: A Genetic Testing Program for Patients with Chronic Kidney Disease

Read more
 PDF
 PDF

03-2021

Corporate Presentation

 PDF

10-22-2020

2020 ASN Poster

Poster: Prasad Devarajan, M.D., Cincinnati Children's Hospital, OH, USA, presented KIDNEYCODE: A Genetic Testing Program for Patients with Chronic Kidney Disease. 

 PDF